BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 21240604)

  • 1. [Progressive multifocal leukoencephalopathy under natalizumab. Initial possibilities for risk stratification?].
    Warnke C; Adams O; Gold R; Hartung HP; Hohlfeld R; Wiendl H; Kieseier BC
    Nervenarzt; 2011 Apr; 82(4):475-80. PubMed ID: 21240604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
    Clifford DB; De Luca A; Simpson DM; Arendt G; Giovannoni G; Nath A
    Lancet Neurol; 2010 Apr; 9(4):438-46. PubMed ID: 20298967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive multifocal leukoencephalopathy and natalizumab.
    Hellwig K; Gold R
    J Neurol; 2011 Nov; 258(11):1920-8. PubMed ID: 21647730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.
    Yousry TA; Major EO; Ryschkewitsch C; Fahle G; Fischer S; Hou J; Curfman B; Miszkiel K; Mueller-Lenke N; Sanchez E; Barkhof F; Radue EW; Jäger HR; Clifford DB
    N Engl J Med; 2006 Mar; 354(9):924-33. PubMed ID: 16510746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Progressive multifocal leukoencephalopathy. Undesirable side effect of immunotherapy].
    Hartung HP; Warnke C; Hohlfeld R; Kieseier BC
    Nervenarzt; 2009 Oct; 80(10):1143-4, 1146-8, 1150-3. PubMed ID: 19357826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
    Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
    J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
    Bacchetta F; Mathias A; Schluep M; Du Pasquier R
    Mult Scler; 2017 Feb; 23(2):300-303. PubMed ID: 28165319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?
    Warnke C; Menge T; Hartung HP; Racke MK; Cravens PD; Bennett JL; Frohman EM; Greenberg BM; Zamvil SS; Gold R; Hemmer B; Kieseier BC; Stüve O
    Arch Neurol; 2010 Aug; 67(8):923-30. PubMed ID: 20697042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients.
    Rossi F; Newsome SD; Viscidi R
    Mol Cell Probes; 2015 Feb; 29(1):54-62. PubMed ID: 25483260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Plavina T; Subramanyam M; Bloomgren G; Richman S; Pace A; Lee S; Schlain B; Campagnolo D; Belachew S; Ticho B
    Ann Neurol; 2014 Dec; 76(6):802-12. PubMed ID: 25273271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
    Landy DC; Hecht EM
    Clin Neuropharmacol; 2014; 37(2):45-51. PubMed ID: 24614671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
    Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
    Cutter GR; Stüve O
    Mult Scler; 2014 Sep; 20(10):1304-5. PubMed ID: 24812045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
    Baldwin KJ; Hogg JP
    Curr Opin Neurol; 2013 Jun; 26(3):318-23. PubMed ID: 23493158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
    Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I
    Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.
    Villar LM; Costa-Frossard L; Masterman T; Fernandez O; Montalban X; Casanova B; Izquierdo G; Coret F; Tumani H; Saiz A; Arroyo R; Fink K; Leyva L; Espejo C; Simó-Castelló M; García-Sánchez MI; Lauda F; Llufriú S; Álvarez-Lafuente R; Olascoaga J; Prada A; Oterino A; de Andrés C; Tintoré M; Ramió-Torrentà L; Rodríguez-Martín E; Picón C; Comabella M; Quintana E; Agüera E; Díaz S; Fernandez-Bolaños R; García-Merino JA; Landete L; Menéndez-González M; Navarro L; Pérez D; Sánchez-López F; Serrano-Castro PJ; Tuñón A; Espiño M; Muriel A; Bar-Or A; Álvarez-Cermeño JC
    Ann Neurol; 2015 Mar; 77(3):447-57. PubMed ID: 25581547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification.
    Pitarokoili K; Gold R
    Nat Rev Neurol; 2017 Dec; 13(12):710-712. PubMed ID: 29146954
    [No Abstract]   [Full Text] [Related]  

  • 19. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.
    McGuigan C; Craner M; Guadagno J; Kapoor R; Mazibrada G; Molyneux P; Nicholas R; Palace J; Pearson OR; Rog D; Young CA
    J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):117-25. PubMed ID: 26492930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE
    Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.